Rate My Professor Mark Schulper

Mark Sculpher is Professor of Health Economics and Head of Department at the Centre for Health Economics, University of York, where he has been based since 1997. Prior to this, he worked at the Health Economics Research Group at Brunel University from 1988 to 1997 and served as a visitor in the Department of Clinical Epidemiology and Biostatistics at McMaster University in Canada in 1998. He is also Co-Director of the Policy Research Unit in Economic Evaluation of Health and Care Interventions. Sculpher leads courses at the Centre for Health Economics, including Decision Analytic Modelling for Economic Evaluation and co-leads Online Advanced Methods of Economic Evaluation for Health Technology Assessment.

His research specializations encompass decision analytic modelling, analysis of uncertainty and heterogeneity, pharmaceutical policy, economic evaluation methods, and decision making, applied to heart disease, cancer, medical devices, diagnostics, and public health. He has over 300 peer-reviewed publications, including key books 'Methods for the Economic Evaluation of Health Care Programmes' (Oxford University Press, 2015, co-authored with Drummond, Claxton, Torrance, and Stoddart) and 'Decision Modelling for Health Economic Evaluation' (Oxford University Press, 2006, co-authored with Briggs and Claxton). Other prominent works include the economic evaluation of the CESAR trial (2009) and recommendations from the Second Panel on Cost-Effectiveness in Health and Medicine (2016). Sculpher received the NIHR Senior Investigator (Emeritus) award, was elected Fellow of the Academy of Medical Sciences in 2024, and served as former President of the International Society for Pharmacoeconomics and Outcomes Research. He chaired NICE's 2004 Task Group on methods guidance for economic evaluation, served on NICE Technology Appraisal Committee (2004-2008), Public Health Interventions Advisory Committee (2006-2009), and Diagnostics Advisory Committee (2010-2020), as well as the UK NHS Health Technology Assessment Programme Commissioning Board (2007-2010), NIHR/MRC Methodology panels, and various international advisory groups. He is a member of editorial boards for Pharmacoeconomics and Applied Health Economics and Health Policy.